Literature DB >> 27882182

Disease progression in Chinese patients with hepatitis C virus RNA-positive infection via blood transfusion.

Yan-Feng Pan1, Yan Zheng1, Tao Qin2, Lei Feng3, Qian Zhang1, Xiao-Gong Ping1, Yan-Ting Pan4, Xiao-Ping Wang1, Li Bai1, Hua-Hua Li1.   

Abstract

The majority of patients with hepatitis C virus (HCV) in China were infected via blood transfusion prior to the year 1996. In this systematic retrospective cohort study, disease progression in 804 consecutive patients with transfusion-acquired HCV is investigated. In addition, the occurrence of compensated cirrhosis, decompensated cirrhosis and hepatocellular carcinoma (HCC) is analyzed among these patients, along with the risk factors for disease progression. Patients with cirrhosis or HCC were classified as the serious development group (SD group) and the remaining patients with chronic hepatitis were classified as the hepatitis group (H group). Significant differences were found between the two groups in age at the time of infection, duration of infection and age at the time of observation. SD group patients were significantly older at the time of transfusion (33.73 vs. 23.56 years; P<0.001), with a significantly longer mean duration of HCV infection (21.88 vs. 21.15 years; P=0.029) compared with that in the H group. Male gender and age at the time of transfusion were significant risk factors for HCC (OR=2.48, P=0.031 and OR=1.07, P=0.002, respectively). Age was a significant risk factor for disease progression in older Chinese patients with transfusion-acquired HCV, and there were significant differences in the prevalence of compensated cirrhosis, decompensated cirrhosis and HCC between the age groups (P<0.001), suggesting that more patients with HCV may develop cirrhosis or HCC in their third and fourth decades of infection. Results of the present study will be helpful for predicting disease progression in Chinese patients with HCV infected via blood transfusion.

Entities:  

Keywords:  blood transfusion; cirrhosis; hepatitis C; hepatocellular carcinoma; risk factors

Year:  2016        PMID: 27882182      PMCID: PMC5103844          DOI: 10.3892/etm.2016.3792

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  46 in total

Review 1.  Long-term outcome of vertically acquired and post-transfusion hepatitis C infection in children.

Authors:  Sanguansak Rerksuppaphol; Winita Hardikar; Gregory J Dore
Journal:  J Gastroenterol Hepatol       Date:  2004-12       Impact factor: 4.029

2.  Body mass index is associated with age-at-onset of HCV-infected hepatocellular carcinoma patients.

Authors:  Takumi Akiyama; Toshihiko Mizuta; Seiji Kawazoe; Yuichiro Eguchi; Yasunori Kawaguchi; Hirokazu Takahashi; Iwata Ozaki; Kazuma Fujimoto
Journal:  World J Gastroenterol       Date:  2011-02-21       Impact factor: 5.742

3.  Detection of hepatitis C virus RNA in acute non-A, non-B hepatitis as an early diagnostic tool.

Authors:  N Kato; O Yokosuka; K Hosoda; Y Ito; M Ohto; M Omata
Journal:  Biochem Biophys Res Commun       Date:  1993-04-30       Impact factor: 3.575

4.  Evaluating progression of liver disease from repeat liver biopsies in children with chronic hepatitis C: a retrospective study.

Authors:  Parvathi Mohan; Bruce A Barton; Michael R Narkewicz; Jean P Molleston; Regino P Gonzalez-Peralta; Philip Rosenthal; Karen F Murray; Barbara Haber; Kathleen B Schwarz; Zachary D Goodman
Journal:  Hepatology       Date:  2013-09-30       Impact factor: 17.425

5.  Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth.

Authors:  Maria Antonietta Casiraghi; Massimo De Paschale; Luisa Romanò; Renato Biffi; Agnese Assi; Giorgio Binelli; Alessandro Remo Zanetti
Journal:  Hepatology       Date:  2004-01       Impact factor: 17.425

6.  Distribution of hepatitis C virus genotypes in Chinese patients with chronic hepatitis C: correlation with patients' characteristics and clinical parameters.

Authors:  Zhi Xia Dong; Hui Juan Zhou; Jian Hua Wang; Xiao Gang Xiang; Yan Zhuang; Si Min Guo; Hong Lian Gui; Gang De Zhao; Wei Liang Tang; Hui Wang; Qing Xie
Journal:  J Dig Dis       Date:  2012-11       Impact factor: 2.325

7.  Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities.

Authors:  E Silini; F Bono; A Cividini; A Cerino; S Bruno; S Rossi; G Belloni; B Brugnetti; E Civardi; L Salvaneschi
Journal:  Hepatology       Date:  1995-02       Impact factor: 17.425

8.  Clinical outcomes after transfusion-associated hepatitis C.

Authors:  M J Tong; N S el-Farra; A R Reikes; R L Co
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

9.  The natural history of hepatitis C virus (HCV) infection.

Authors:  Stephen L Chen; Timothy R Morgan
Journal:  Int J Med Sci       Date:  2006-04-01       Impact factor: 3.738

10.  Global distribution and prevalence of hepatitis C virus genotypes.

Authors:  Jane P Messina; Isla Humphreys; Abraham Flaxman; Anthony Brown; Graham S Cooke; Oliver G Pybus; Eleanor Barnes
Journal:  Hepatology       Date:  2014-07-28       Impact factor: 17.425

View more
  3 in total

1.  Relationship between sex hormones and RIG-I signaling in peripheral blood mononuclear cells of patients infected with hepatitis C virus.

Authors:  Fang Ping Wang; Ping An Zhang; Xiao Yan Yang
Journal:  Exp Ther Med       Date:  2017-07-24       Impact factor: 2.447

Review 2.  Hepatitis C virus cure with direct acting antivirals: Clinical, economic, societal and patient value for China.

Authors:  Qing Xie; Jian-Wei Xuan; Hong Tang; Xiao-Guang Ye; Peng Xu; I-Heng Lee; Shan-Lian Hu
Journal:  World J Hepatol       Date:  2019-05-27

3.  Prevalence of HCV Infection Among Hemodialysis Patients in Lanzhou of Northwestern China.

Authors:  Kai Bao; Jijun Chen; Ruifang Liu; Yuanyuan Xiang; Wenlong Gao
Journal:  Infect Drug Resist       Date:  2022-09-22       Impact factor: 4.177

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.